Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? - 20/03/18
, Palita Hansakul a, 1, 2 , Alastair M. Thompson b , Huong Le-Petross a , Vicente Valero c , Roland Bassett d , Monica L. Huang a , Lumarie Santiago a , Beatriz E. Adrada a Abstract |
Background |
To determine the cancer yield of stereotactic biopsy of suspicious calcifications identified within 24 months after breast conservation therapy (BCT).
Methods |
Retrospective review of stereotactic biopsies performed during 2009–2013 for suspicious calcifications in the ipsilateral breast of patients who completed BCT.
Results |
94/2773 (3.4%) had stereotactic biopsies for suspicious calcifications in the ipsilateral breast; 7/94 (7.4%) had DCIS (6) or invasive (1) cancer; 5/7 occurred in the same breast quadrant as the primary. All 7 originally had negative surgical margins (≥2 mm); 6 received whole breast irradiation, and 2 received adjuvant chemotherapy + endocrine therapy. Median time to detection was 11 months (range, 6–20 months). There was a strong association between calcification morphology (particularly pleomorphic) and likelihood of malignancy (p = 0.008).
Conclusions |
Stereotactic biopsy of calcifications identified within 24 months post-BCT has a 7% cancer yield. Tissue biopsy should be performed rather than imaging followup alone when breast calcifications have suspicious morphology.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Breast conservation, Calcifications, Mammography, Stereotactic biopsy
Plan
Vol 215 - N° 4
P. 693-698 - avril 2018 Retour au numéro
Article précédent
- Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment
- Zachary Kozick, Ammar Hashmi, James Dove, Marie Hunsinger, Tania Arora, Jeffrey Wild, Mohsen Shabahang, Joseph Blansfield
- Stratifying SLN incidence in intermediate thickness melanoma patients
- James M. Chang, Heidi E. Kosiorek, Amylou C. Dueck, Stanley P.L. Leong, John T. Vetto, Richard L. White, Eli Avisar, Vernon K. Sondak, Jane L. Messina, Jonathan S. Zager, Carlos Garberoglio, Mohammed Kashani-Sabet, Barbara A. Pockaj
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?